Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Tormey
D C
DC
University of Wisconsin Comprehensive Cancer Center, Madison.
Gray
R
R
Falkson
H C
HC
Gilchrist
K
K
Abeloff
M D
MD
Falkson
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005474:Fluoxymesterone / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D011241:Prednisone / Q000008:administration & dosage; D011960:Receptors, Estrogen / Q000032:analysis; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D013852:Thiotepa / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage
D011960:Receptors, Estrogen; D013629:Tamoxifen; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013852:Thiotepa; D005474:Fluoxymesterone; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate